
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis
 - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F3920500003BACCC0A275A.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="nop" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC5099992/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099992/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Neuro-Oncology Practice" /><meta name="citation_title" content="A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis&#10;" /><meta name="citation_author" content="Motomasa Furuse" /><meta name="citation_author" content="Naosuke Nonoguchi" /><meta name="citation_author" content="Toshihiko Kuroiwa" /><meta name="citation_author" content="Susumu Miyamoto" /><meta name="citation_author" content="Yoshiki Arakawa" /><meta name="citation_author" content="Jun Shinoda" /><meta name="citation_author" content="Kazuhiro Miwa" /><meta name="citation_author" content="Toshihiko Iuchi" /><meta name="citation_author" content="Koji Tsuboi" /><meta name="citation_author" content="Kiyohiro Houkin" /><meta name="citation_author" content="Shunsuke Terasaka" /><meta name="citation_author" content="Yusuke Tabei" /><meta name="citation_author" content="Hideo Nakamura" /><meta name="citation_author" content="Motoo Nagane" /><meta name="citation_author" content="Kazuhiko Sugiyama" /><meta name="citation_author" content="Mizuhiko Terasaki" /><meta name="citation_author" content="Tatsuya Abe" /><meta name="citation_author" content="Yoshitaka Narita" /><meta name="citation_author" content="Nobuhito Saito" /><meta name="citation_author" content="Akitake Mukasa" /><meta name="citation_author" content="Kuniaki Ogasawara" /><meta name="citation_author" content="Takaaki Beppu" /><meta name="citation_author" content="Toshihiro Kumabe" /><meta name="citation_author" content="Tadashi Nariai" /><meta name="citation_author" content="Naohiro Tsuyuguchi" /><meta name="citation_author" content="Eiji Nakatani" /><meta name="citation_author" content="Shoko Kurisu" /><meta name="citation_author" content="Yoko Nakagawa" /><meta name="citation_author" content="Shin-Ichi Miyatake" /><meta name="citation_publication_date" content="2016/12" /><meta name="citation_issue" content="4" /><meta name="citation_volume" content="3" /><meta name="citation_firstpage" content="272" /><meta name="citation_doi" content="10.1093/nop/npv064" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC5099992/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC5099992/" /><meta name="citation_pmid" content="27833757" /><meta name="DC.Title" content="A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis&#10;" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Oxford University Press" /><meta name="DC.Contributor" content="Motomasa Furuse" /><meta name="DC.Contributor" content="Naosuke Nonoguchi" /><meta name="DC.Contributor" content="Toshihiko Kuroiwa" /><meta name="DC.Contributor" content="Susumu Miyamoto" /><meta name="DC.Contributor" content="Yoshiki Arakawa" /><meta name="DC.Contributor" content="Jun Shinoda" /><meta name="DC.Contributor" content="Kazuhiro Miwa" /><meta name="DC.Contributor" content="Toshihiko Iuchi" /><meta name="DC.Contributor" content="Koji Tsuboi" /><meta name="DC.Contributor" content="Kiyohiro Houkin" /><meta name="DC.Contributor" content="Shunsuke Terasaka" /><meta name="DC.Contributor" content="Yusuke Tabei" /><meta name="DC.Contributor" content="Hideo Nakamura" /><meta name="DC.Contributor" content="Motoo Nagane" /><meta name="DC.Contributor" content="Kazuhiko Sugiyama" /><meta name="DC.Contributor" content="Mizuhiko Terasaki" /><meta name="DC.Contributor" content="Tatsuya Abe" /><meta name="DC.Contributor" content="Yoshitaka Narita" /><meta name="DC.Contributor" content="Nobuhito Saito" /><meta name="DC.Contributor" content="Akitake Mukasa" /><meta name="DC.Contributor" content="Kuniaki Ogasawara" /><meta name="DC.Contributor" content="Takaaki Beppu" /><meta name="DC.Contributor" content="Toshihiro Kumabe" /><meta name="DC.Contributor" content="Tadashi Nariai" /><meta name="DC.Contributor" content="Naohiro Tsuyuguchi" /><meta name="DC.Contributor" content="Eiji Nakatani" /><meta name="DC.Contributor" content="Shoko Kurisu" /><meta name="DC.Contributor" content="Yoko Nakagawa" /><meta name="DC.Contributor" content="Shin-Ichi Miyatake" /><meta name="DC.Date" content="2016 Dec" /><meta name="DC.Identifier" content="10.1093/nop/npv064" /><meta name="DC.Language" content="en" /><meta property="og:title" content="A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis&#10;" /><meta property="og:type" content="article" /><meta property="og:description" content="Brain radiation necrosis (BRN) can be a complication of radiotherapy for primary and secondary brain tumors, as well as head and neck tumors. Since vascular endothelial growth factor (VEGF) is also a vascular permeability factor in the brain, bevacizumab, ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099992/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5099992/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2697/">Neurooncol Pract</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/278756/">v.3(4); 2016 Dec</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC5099992
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC5099992/pdf/npv064.pdf" class="int-view">PDF (4.2M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/5099992/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/5099992/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="5099992" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5099992%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="pRaxOh9jbBPvCzhbe84cOwZqgkyeWa0PcKd6xIGm6E2frWA0kezIMGblPYYYMnpE">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5099992%2F&amp;text=A%20prospective%2C%20multicentre%2C%20single-arm%20clinical%20trial%20of%20bevacizumab%20for%20patients%20with%20surgically%20untreatable%2C%20symptomatic%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5099992%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099992/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC5099992/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/27833757/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC5099992/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/27833757/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC5099992/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/5099992/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2697/">Neurooncol Pract</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/278756/">v.3(4); 2016 Dec</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC5099992
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-nop.png" alt="Logo of nop" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://academic.oup.com/nop" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Neurooncol Pract.</span> 2016 Dec; 3(4): 272–280. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2016 Jan 7. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1093%2Fnop%2Fnpv064" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1093/nop/npv064</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC5099992</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/27833757">27833757</a></div></div></div><h1 class="content-title">A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis<sup><sup>&#x02020;</sup></sup>
</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Furuse%20M%5BAuthor%5D">Motomasa Furuse</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nonoguchi%20N%5BAuthor%5D">Naosuke Nonoguchi</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kuroiwa%20T%5BAuthor%5D">Toshihiko Kuroiwa</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Miyamoto%20S%5BAuthor%5D">Susumu Miyamoto</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Arakawa%20Y%5BAuthor%5D">Yoshiki Arakawa</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shinoda%20J%5BAuthor%5D">Jun Shinoda</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Miwa%20K%5BAuthor%5D">Kazuhiro Miwa</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Iuchi%20T%5BAuthor%5D">Toshihiko Iuchi</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tsuboi%20K%5BAuthor%5D">Koji Tsuboi</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Houkin%20K%5BAuthor%5D">Kiyohiro Houkin</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Terasaka%20S%5BAuthor%5D">Shunsuke Terasaka</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tabei%20Y%5BAuthor%5D">Yusuke Tabei</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nakamura%20H%5BAuthor%5D">Hideo Nakamura</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nagane%20M%5BAuthor%5D">Motoo Nagane</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sugiyama%20K%5BAuthor%5D">Kazuhiko Sugiyama</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Terasaki%20M%5BAuthor%5D">Mizuhiko Terasaki</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Abe%20T%5BAuthor%5D">Tatsuya Abe</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Narita%20Y%5BAuthor%5D">Yoshitaka Narita</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Saito%20N%5BAuthor%5D">Nobuhito Saito</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mukasa%20A%5BAuthor%5D">Akitake Mukasa</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ogasawara%20K%5BAuthor%5D">Kuniaki Ogasawara</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Beppu%20T%5BAuthor%5D">Takaaki Beppu</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kumabe%20T%5BAuthor%5D">Toshihiro Kumabe</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nariai%20T%5BAuthor%5D">Tadashi Nariai</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tsuyuguchi%20N%5BAuthor%5D">Naohiro Tsuyuguchi</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nakatani%20E%5BAuthor%5D">Eiji Nakatani</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kurisu%20S%5BAuthor%5D">Shoko Kurisu</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nakagawa%20Y%5BAuthor%5D">Yoko Nakagawa</a>, and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Miyatake%20SI%5BAuthor%5D">Shin-Ichi Miyatake</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup></div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139730956630976_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139730956630976_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139730956630976_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139730956630976_ai" style="display:none"><div class="fm-affl" id="aff-a.l.b.f.ad">
Department of Neurosurgery, Osaka Medical College, Takatsuki, Osaka, Japan (M.F., N.N., T.K., S.-I.M.); Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan (S.M., Y.A.); Department of Neurosurgery, Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, Minokamo, Japan (J.S., K.M.); Division of Neurological Surgery, Chiba Cancer Center, Chiba, Japan (T.I.); Proton Medical Research Center, University of Tsukuba, Tsukuba, Japan (K.T.); Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan (K.H., S.T.); Department of Neurosurgery, Japanese Red Cross Medical Center, Tokyo, Japan (Y.T.); Department of Neurosurgery, Kumamoto University Graduate School of Medical Science, Kumamoto, Japan (H.N.); Department of Neurosurgery, Kyorin University Faculty of Medicine, Mitaka, Japan (M.N.); Department of Clinical Oncology and Neuro-oncology Program, Hiroshima University Hospital, Hiroshima, Japan (K.S.); Department of Neurosurgery, Kurume University School of Medicine, Kurume, Japan (M.T.); Department of Neurosurgery, Oita University Faculty of Medicine, Oita, Japan (T.A.); Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan (Y.N.); Department of Neurosurgery, The University of Tokyo, Tokyo, Japan (N.S., A.M.); Department of Neurosurgery, Iwate Medical University, Morioka, Japan (K.O.); Department of Neurosurgery, Division of Hyperbaric Medicine, Iwate Medical University, Morioka, Japan (T.B.); Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Japan (T.Kum); Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan (T.N.); Department of Neurosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan (N.T.); Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan (E.N., S.K., Y.N.)</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="corresp-a.l.b.g.a"><strong>Corresponding Author:</strong> Dr. Shin-Ichi Miyatake, Department of Neurosurgery, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan (<a href="mailto:dev@null" data-email="pj.ca.dem-akaso.hop@070uen" class="oemail">pj.ca.dem-akaso.hop@070uen</a>).</div><div>Contributed by <sup>&#x02020;</sup>Some parts of this manuscript were presented at the 27th Annual Meeting of JASTRO in Yokohama, Japan in December 2014.</div></div><div class="fm-article-notes hide half_rhythm" id="idm139730956630976_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2015 Jul 15</div></div><div class="permissions half_rhythm hide" id="idm139730956630976_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.</div><div class="license half_rhythm">This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<a href="http://creativecommons.org/licenses/by-nc/3.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by-nc/3.0/</a>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin">
Supplementary Data
</div>

<div><a href="/pmc/articles/PMC5099992/bin/supp_3_4_272__index.html" data-ga-action="click_feat_suppl">supp_3_4_272__index.html</a><span style="color:gray"> (1.0K)</span></div><div class="small guid">GUID: C6E51DA4-3DA2-4CFF-99A3-3F306D6ACCEF</div>
<div><a href="/pmc/articles/PMC5099992/bin/supp_npv064_npv064supp.pdf" data-ga-action="click_feat_suppl">supp_npv064_npv064supp.pdf</a><span style="color:gray"> (1.3M)</span></div><div class="small guid">GUID: 2EA4911B-F1A7-4B6C-9B45-27055F166B17</div>
</div></dd></dl></div><div id="abstract-a.l.b.r" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.l.b.rtitle">Abstract</h2><!--article-meta--><div><div id="sec-a.l.b.r.a" class="sec sec-first"><h3 id="sec-a.l.b.r.atitle">Background</h3><p class="p p-first-last">Brain radiation necrosis (BRN) can be a complication of radiotherapy for primary and secondary brain tumors, as well as head and neck tumors. Since vascular endothelial growth factor (VEGF) is also a vascular permeability factor in the brain, bevacizumab, a humanized antibody that inhibits VEGF, would be expected to reduce perilesional edema that often accompanies BRN.</p></div><div id="sec-a.l.b.r.b" class="sec"><h3 id="sec-a.l.b.r.btitle">Methods</h3><p class="p p-first-last">Patients with surgically untreatable, symptomatic BRN refractory to conventional medical treatments (eg, corticosteroid, anticoagulants, or hyperbaric oxygen therapy) were enrolled. We judged that a major cause of perilesional edema with a lesion-to-normal brain ratio &#x02264;1.8 on <sup>11</sup>C-methionine or &#x02264;2.5 on <sup>18</sup>F-boronophenylalanine PET was BRN, not tumor recurrence, and 6 cycles of biweekly bevacizumab (5 mg/kg) were administered. The primary endpoint was a &#x02265;30% reduction from the patients' registration for perilesional edema continuing for &#x02265;1 month.</p></div><div id="sec-a.l.b.r.c" class="sec"><h3 id="sec-a.l.b.r.ctitle">Results</h3><p class="p p-first-last">Of the 41 patients enrolled, 38 were fully eligible for the response assessment. The primary endpoint was achieved in 30 of the 38 (78.9%) patients at 3.0 months (median) after enrollment. Sixteen patients (42.1%) experienced improvement of their Karnofsy Performance Score. Corticosteroid use could be reduced in 29 patients (76.3%). Adverse events at grade &#x02265;3 occurred in 10 patients (24.4%).</p></div><div id="sec-a.l.b.r.d" class="sec sec-last"><h3 id="sec-a.l.b.r.dtitle">Conclusions</h3><p class="p p-first-last">Bevacizumab treatment offers certain clinical benefits for patients with surgically untreatable, symptomatic BRN. The determination of BRN using amino-acid PET, not biopsy, is adequate and less invasive for determining eligibility to receive bevacizumab.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Bevacizumab, brain radiation necrosis, positron emission tomography, vascular endothelial growth factor</span></div></div><div id="body-a.m" class="tsec sec"><h2 class="headless nomenu"></h2><p class="p p-first">Radiotherapy contributes to the local control of brain tumors, but high-dose radiotherapy or multiple radiotherapy sessions often increase the incidence of severe radiation injury. Acute radiation injuries can usually be controlled by corticosteroids, but the efficacy of these drugs is limited for late-phase radiation injuries such as brain radiation necrosis (BRN). BRN sometimes impairs patients' clinical status, resulting in worsened quality of life even if the brain tumor is stable. Since vascular endothelial growth factor (VEGF) is also a vascular permeability factor in the brain,<sup><a href="#NPV064C1" rid="NPV064C1" class=" bibr popnode">1</a></sup> bevacizumab, a humanized antibody that inhibits VEGF, would be expected to reduce perilesional edema that often accompanies BRN.<sup><a href="#NPV064C2" rid="NPV064C2" class=" bibr popnode">2</a>&#x02013;<a href="#NPV064C6" rid="NPV064C6" class=" bibr popnode">6</a></sup> However, bevacizumab's optimal dose, dosing interval, and duration of efficacy have not been fully defined.</p><p>Symptomatic BRN is accompanied by progressive, perilesional edema volume on T2-weighted MR images, and impairs patients' quality of life. With the use of ordinary imaging modalities such as MRI, it is not easy to determine whether worsening perilesional edema is caused mainly by BRN or by tumor progression; the histological analysis of the lesion is the gold standard for diagnosis. Pure BRN is rare in malignant brain tumors, and some tumor cells usually remain somewhere in or around the BRN (<a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplemental material, Fig. S1</a>).</p><p>There are a number of noninvasive neuroimaging techniques to evaluate patients for BRN; these include CT, MRI, and PET. The authors have experience with PET using amino acid tracers for CNS lesions<sup><a href="#NPV064C7" rid="NPV064C7" class=" bibr popnode">7</a>&#x02013;<a href="#NPV064C12" rid="NPV064C12" class=" bibr popnode">12</a></sup> and believe that it is useful for distinguishing BRN from tumor growth. The contrast between tumor and normal tissue shown by PET using some types of amino acids is much higher than that shown by <sup>18</sup>F-fluorodeoxyglucose PET. We previously investigated the cut-off value for amino-acid PET that could discriminate tumor progression from pure BRN or BRN with remaining tumor cells.<sup><a href="#NPV064C13" rid="NPV064C13" class=" bibr popnode">13</a></sup>
</p><p class="p">Here we conducted a prospective, multicenter, single-arm clinical trial to evaluate bevacizumab's safety and efficacy in patients with surgically untreatable symptomatic BRN refractory to conventional medical treatments. We used amino-acid PET to examine patients suspected of having BRN. For patient eligibility, we classified BRN on the basis of the biological lesion activity as an alternative to histopathological diagnosis requiring invasive surgical procedures.</p></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">Patients and Methods</h2><div id="s2a" class="sec sec-first"><h3 id="s2atitle">Patients</h3><p class="p p-first">Patients were eligible if: (i) they had been treated for a brain tumor or head/neck cancer with radiotherapy at least 3 months prior to registration in this trial; (ii) they had progressive perilesional edema that clinically seemed to be caused by BRN; (iii) they had symptoms that were refractory to conventional medical treatment such as corticosteroids and anticoagulants lasting 1 month or longer; (iv) the lesion was enhanced by contrast media, was accompanied by perilesional edema, and was not resectable for any reason; (v) they had a KPS score of 60 or higher; and (vi) they had adequate hematologic, hematic, and renal function. In the present BRN cases after radiotherapy for metastatic brain tumors, systemically or locally active lesions were not detected by radiographic examinations. Tumor markers were within normal ranges otherwise. Further details of the inclusion and exclusion criteria are provided in the <a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplementary Materials</a>. The radiation modality and doses in individual cases are listed in <a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplementary material, Table S1</a>.</p><p class="p p-last">The protocol was approved by the Institutional Review Board at each participating institution. Written informed consent was obtained from all patients.</p></div><div id="s2b" class="sec"><h3 id="s2btitle">Assessment of BRN by amino-acid PET</h3><p class="p p-first-last">We classified BRN using the uptake of tracer on amino-acid PET, and the lesions were examined by <sup>11</sup>C-methionine (MET) or <sup>18</sup>F-boronophenylalanine (BPA) PET. Circular regions of interest (ROIs) were placed over the lesion and the contralateral white matter. The lesion-to-normal tissue (L/N) ratio of tracer uptake was calculated by dividing the lesion ROI by the contralateral white matter ROI. A lesion with an L/N ratio less than or equal to 1.8 on <sup>11</sup>C-MET PET or greater than or equal to 2.5 on <sup>18</sup>F-BPA-PET was classified as BRN, indicating that BRN was the dominant cause of the perilesional edema. These cut-off values were determined by the trial's steering committee, based on previous findings.<sup><a href="#NPV064C8" rid="NPV064C8" class=" bibr popnode">8</a>,<a href="#NPV064C13" rid="NPV064C13" class=" bibr popnode">13</a>,<a href="#NPV064C14" rid="NPV064C14" class=" bibr popnode">14</a></sup>
</p></div><div id="s2c" class="sec"><h3 id="s2ctitle">Treatment</h3><p class="p p-first-last">All patients received intravenous bevacizumab at 5 mg/kg biweekly as a cycle, until 6 cycles were completed. After 3 cycles, MRI was conducted. If no negative change was detected by MRI, the patient continued the bevacizumab. Treatment was discontinued if the patient experienced certain adverse events as described in the <a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplementary Materials</a>.</p></div><div id="s2d" class="sec"><h3 id="s2dtitle">Measurement on MRI</h3><p class="p p-first">The radiological reduction of the perilesional edema was measured by MRI. A volumetric analysis was performed using U.S. FDA-cleared imaging software (Osirix MD v.2.5.1, Pixmeo, Bernex, Switzerland). In each slice, the area of hyperintensity was measured on T2-weighted or fluid-attenuated inversion recovery (FLAIR) images. Hyperintense lesions were automatically traced as ROIs by means of the lower threshold of perilesional edema, and edema was defined referring to the upper limit of the 95% confidence interval (CI) for the normal brain tissue value. Volume was calculated as the sum of all areas of ROIs multiplied by the slice interval.</p><p class="p p-last">MR images were obtained at baseline, after 3 cycles, 6 cycles and then at 1 month and every 3 months after the completion of treatment (see Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F3" rid-ob="ob-NPV064F3" co-legend-rid="lgnd_NPV064F3"><span>3</span></a>). Reductions in contrast-enhanced lesions were also evaluated in the same way as described above. The diagnostic MRI central review was performed by two neurosurgeons, as mentioned in the Acknowledgements.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="NPV064F3" co-legend-rid="lgnd_NPV064F3"><a href="/pmc/articles/PMC5099992/figure/NPV064F3/" target="figure" rid-figpopup="NPV064F3" rid-ob="ob-NPV064F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139730950098864"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5099992_npv06403.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is npv06403.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5099992/bin/npv06403.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139730950098864"><a target="object" rel="noopener" href="/pmc/articles/PMC5099992/figure/NPV064F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_NPV064F3"><div><a class="figpopup" href="/pmc/articles/PMC5099992/figure/NPV064F3/" target="figure" rid-figpopup="NPV064F3" rid-ob="ob-NPV064F3">Fig.&#x000a0;3.</a></div><!--caption a7--><div class="caption"><p>Chronological changes in the volumes of (A) the perilesional edema and (B) the contrast-enhanced lesions, compared to the baseline values. In panels A and B, the values are plotted as the geometric mean and SE. MR images show representative chronological changes in perilesional edema on FLAIR images (upper column) and contrast-enhanced lesions on gadolinium-enhanced, T1-weighted images (lower column). Images at baseline, after 3 cycles, 6 cycles, at 1 month, and every 3 months until 12 months after completion of the treatment are shown from left to right.</p></div></div></div></div><div id="s2e" class="sec"><h3 id="s2etitle">Evaluation of Efficacy and Safety</h3><p class="p p-first-last">The primary endpoint was remission of perilesional edema on MRI. Response was defined as a &#x02265;30% reduction in perilesional edema from the baseline. Remission was defined as a response lasting at least 4 weeks. Progression was defined as a 25% or greater increase in perilesional edema from the minimal value. Secondary endpoints were the reduction of corticosteroid use, improvement of KPS, recurrent radiation necrosis (progression), and reduction in the contrast-enhanced lesion's volume. Steroid usage and KPS were recorded at the time of each scheduled assessment. The incidence of adverse events was assessed until 1 month after treatment completion, according to the Common Terminology Criteria for Adverse Events (CTCAE), v.4.0.</p></div><div id="s2f" class="sec sec-last"><h3 id="s2ftitle">Statistical Analysis</h3><p class="p p-first">Our primary objective was to elucidate the reduction of perilesional edema by bevacizumab in terms of area measured using MRI. In the 27 symptomatic BRN patients treated at Osaka Medical College between June 2004 and July 2009, the response rate to treatments other than bevacizumab was 14.8% (4/27).<sup><a href="#NPV064C15" rid="NPV064C15" class=" bibr popnode">15</a></sup> Thus, the response rate under the null hypothesis was conservatively assumed to be 20%. The response rate to bevacizumab treatment was presumed to be approximately 45% (under the alternative hypothesis). With a type 1 error of &#x02264;5% in the two-sided binomial test and a power of &#x02265;90%, the estimated required number of patients was 37. Using a 7.5% drop-out rate, we set a target sample size of 40.</p><p>The efficacy evaluation, which included the primary endpoint, was based on the intent-to-treat principle using the full analysis set (FAS) data. We used the Clopper-Pearson method to calculate the CI of the response rate. The evaluation of adverse events was based on a safety analysis set. The incidence of adverse events is expressed as frequency and percentage. We also calculated the geometric mean and standard error (SE) for the percent changes from the baseline values of perilesional edema volume and contrast-enhanced volume, the frequencies for each KPS category (better, unchanged, worse compared with the baseline), and the mean and SE of corticosteroid dose/day at each time point.</p><p class="p p-last">For the time-to-remission and progression evaluations, we estimated the patients' rate curves and median times using the Kaplan-Meier method. As a sensitivity analysis comparing pairs of groups, Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous variables were performed. Data were analyzed using SAS v.9.3 software (SAS Institute, Cary, NC) and R v.3.1.2 software (R Foundation for Statistical Computing, Vienna, Austria).</p></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">Results</h2><div id="s3a" class="sec sec-first"><h3 id="s3atitle">Patients and Treatment</h3><p class="p p-first">Between April 2011 and February 2013, 41 patients from 16 institutions were enrolled in this trial (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F1" rid-ob="ob-NPV064F1" co-legend-rid="lgnd_NPV064F1"><span>1</span></a>). All patients received bevacizumab and none were excluded before treatment. Three cycles of bevacizumab administration were completed in 40 of the patients. Thirty-six of these patients underwent 6 bevacizumab cycles and completed the protocol treatment. Bevacizumab was discontinued due to three adverse events (7.3%): 2 cases of grade 2 intracranial hemorrhages and 1 case of deterioration of neurological status. One patient developed a primary-disease tumor recurrence and 1 patient withdrew consent. Three of the 41 patients were eventually excluded because it was found after registration that they did not meet all of the inclusion criteria. The remaining 38 cases were followed as the FAS.

</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="NPV064F1" co-legend-rid="lgnd_NPV064F1"><a href="/pmc/articles/PMC5099992/figure/NPV064F1/" target="figure" rid-figpopup="NPV064F1" rid-ob="ob-NPV064F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139730956669584"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5099992_npv06401.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is npv06401.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5099992/bin/npv06401.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139730956669584"><a target="object" rel="noopener" href="/pmc/articles/PMC5099992/figure/NPV064F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_NPV064F1"><div><a class="figpopup" href="/pmc/articles/PMC5099992/figure/NPV064F1/" target="figure" rid-figpopup="NPV064F1" rid-ob="ob-NPV064F1">Fig.&#x000a0;1.</a></div><!--caption a7--><div class="caption"><p>CONSORT diagram. Of the 41 patients enrolled in this trial, 40 underwent 3 cycles of bevacizumab. One patient had an adverse event (AE) leading to the discontinuation of bevacizumab. Thirty-eight patients were followed up as the full analysis set (FAS). Thirty-six patients underwent 6 administrations of bevacizumab. Of the 4 patients who discontinued bevacizumab, 2 had AEs. Primary organ tumor recurred in 1 patient and consent was withdrawn by 1 patient. Thirty-eight patients were followed, and 20 patients were completely followed until 12 months after the last administration of bevacizumab (the per protocol set [PPS]).</p></div></div></div><p class="p p-last">Twenty patients completed the 12-month follow-up as the per protocol set (PPS). Eighteen patients were followed but not assessable for a 12-month follow-up due to relapse of brain tumor (8 patients); tumor progression of another organ (1 patient); death (4 patients); and additional interventions (5 patients). The median follow-up period was 13.1 months for the FAS and 12.9 months for the safety analysis set. Table&#x000a0;<a href="/pmc/articles/PMC5099992/table/NPV064TB1/" target="table" class="fig-table-link figpopup" rid-figpopup="NPV064TB1" rid-ob="ob-NPV064TB1" co-legend-rid=""><span>1</span></a> shows the clinical characteristics of the patients.

</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="NPV064TB1"><h3>Table&#x000a0;1.</h3><!--caption a7--><div class="caption"><p>Patient characteristics</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">
<em>n</em> = 38</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years), median (range)</td><td rowspan="1" colspan="1">54.5 (17.0&#x02013;73.0)</td></tr><tr><td colspan="2" rowspan="1">Sex</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">22 (57.9%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">16 (42.1%)</td></tr><tr><td rowspan="1" colspan="1">Karnofsky Performance Status, median (range)</td><td rowspan="1" colspan="1">70 (60&#x02013;100)</td></tr><tr><td colspan="2" rowspan="1">Tumors</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Primary brain tumors</td><td rowspan="1" colspan="1">27 (71.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Secondary brain tumors</td><td rowspan="1" colspan="1">10 (26.3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Adjacent organ</td><td rowspan="1" colspan="1">1 (2.6%)</td></tr><tr><td colspan="2" rowspan="1">Primary brain tumor</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Glioblastoma (WHO grade IV)</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Anaplastic glioma (WHO grade III)</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Glioma (WHO grade II)</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Others</td><td rowspan="1" colspan="1">5</td></tr><tr><td colspan="2" rowspan="1">Origin of metastatic brain tumor</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Lung</td><td rowspan="1" colspan="1">5 (50%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Non-lung</td><td rowspan="1" colspan="1">5 (50%)</td></tr><tr><td rowspan="1" colspan="1">Time from radiotherapy to diagnosis (months), median (range)</td><td rowspan="1" colspan="1">24.1 (3.0&#x02013;140.9)</td></tr><tr><td colspan="2" rowspan="1">Radiotherapy</td></tr><tr><td rowspan="1" colspan="1">&#x02003;SRS</td><td rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1">&#x02003;EBRT</td><td rowspan="1" colspan="1">17</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hypofractionated IMRT</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Proton beam</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;BNCT</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Chemotherapy for tumor</td><td rowspan="1" colspan="1">30 (78.9%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Temozolomide</td><td rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other chemotherapeutic agents</td><td rowspan="1" colspan="1">10</td></tr><tr><td colspan="2" rowspan="1">Treatment for BRN</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Corticosteroids</td><td rowspan="1" colspan="1">38 (100.0%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Vitamin E</td><td rowspan="1" colspan="1">20 (52.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Anticoagulants/antiplatelets</td><td rowspan="1" colspan="1">18 (47.4%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Surgical removal of necrosis</td><td rowspan="1" colspan="1">4 (10.5%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hyperbaric oxygen therapy</td><td rowspan="1" colspan="1">3 (7.9%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Bevacizumab</td><td rowspan="1" colspan="1">1 (2.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Osmotic diuretics</td><td rowspan="1" colspan="1">1 (2.6%)</td></tr><tr><td colspan="2" rowspan="1">Amino-acid PET</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<sup>11</sup>C-methionine</td><td rowspan="1" colspan="1">30 (78.9%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<sup>18</sup>F-boronophenylalanine</td><td rowspan="1" colspan="1">8 (21.1%)</td></tr><tr><td colspan="2" rowspan="1">Lesion-to-normal tissue ratio, median (range)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<sup>11</sup>C-methionine</td><td rowspan="1" colspan="1">1.5 (0.6&#x02013;1.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<sup>18</sup>F-boronophenylalanine</td><td rowspan="1" colspan="1">1.9 (1.5&#x02013;2.3)</td></tr><tr><td colspan="2" rowspan="1">Volume of BRN (mL), median (range)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Perilesional edema</td><td rowspan="1" colspan="1">134.7 (1.9&#x02013;359.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Contrast-enhanced lesion</td><td rowspan="1" colspan="1">7.4 (1.6&#x02013;40.3)</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139730956665552"><a target="object" rel="noopener" href="/pmc/articles/PMC5099992/table/NPV064TB1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="tblfn1"><p class="p p-first-last">Abbreviations: BNCT, boron neutron capture therapy; BRN, brain radiation necrosis; EBRT, external beam radiotherapy; IMRT, intensity-modulated radiotherapy; LGG, low-grade glioma; SRS, stereotactic radiosurgery.</p></div></div></div></div><div id="s3b" class="sec"><h3 id="s3btitle">Efficacy as Evaluated by MRI</h3><p class="p p-first">Of the 38 patients in the FAS, 30 achieved remission of their perilesional edema (78.9%; 95% CI, 62.7%&#x02013;90.4%, <em>P</em> &#x0003c; .0001, binomial test). The median time to remission (responses lasting &#x02265;1 month) from enrollment was 3.03 months (95% CI, 2.86&#x02013;3.85 months) in the FAS (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F2" rid-ob="ob-NPV064F2" co-legend-rid="lgnd_NPV064F2"><span>2</span></a>A). Twenty-seven patients had progression of perilesional edema (71.1%; 95% CI, 54.1%&#x02013;84.6%). The median time to progression of perilesional edema was 9.31 months (95% CI, 5.72&#x02013;10.92 months) (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F2" rid-ob="ob-NPV064F2" co-legend-rid="lgnd_NPV064F2"><span>2</span></a>B). The average volume of perilesional edema reached the minimum (63.0% decrease from the baseline) at 1 month after the last treatment (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F3" rid-ob="ob-NPV064F3" co-legend-rid="lgnd_NPV064F3"><span>3</span></a>A). Subsequently, the volume of perilesional edema increased linearly, but the volume did not reach the baseline value.


</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="NPV064F2" co-legend-rid="lgnd_NPV064F2"><a href="/pmc/articles/PMC5099992/figure/NPV064F2/" target="figure" rid-figpopup="NPV064F2" rid-ob="ob-NPV064F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139730953059504"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5099992_npv06402.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is npv06402.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5099992/bin/npv06402.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139730953059504"><a target="object" rel="noopener" href="/pmc/articles/PMC5099992/figure/NPV064F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_NPV064F2"><div><a class="figpopup" href="/pmc/articles/PMC5099992/figure/NPV064F2/" target="figure" rid-figpopup="NPV064F2" rid-ob="ob-NPV064F2">Fig.&#x000a0;2.</a></div><!--caption a7--><div class="caption"><p>Kaplan-Meier analysis of (A) the cumulative remission rate and (B) the cumulative progression rate of perilesional edema for the 38 patients in the full analysis set (FAS). The median times to remission and progression from enrollment were 3.03 and 9.31 months, respectively.</p></div></div></div><p class="p p-last">Regarding the contrast-enhanced lesions, the average volume reached the minimum (92.8% decrease from baseline) at the last treatment (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F3" rid-ob="ob-NPV064F3" co-legend-rid="lgnd_NPV064F3"><span>3</span></a>B). Subgroup analyses revealed no significant clinical factors associated with remission (<a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplementary material, Table S2</a>). Fisher's exact test revealed no significant differences in the remission rate related to the original tumor pathology (primary vs metastasis, <em>P</em> = .655) or applied radiotherapeutic modality groups (stereotactic radiosurgery vs others, <em>P</em> = .689; high-dose radiotherapy vs others, <em>P</em> = .660). Likewise, the volume of contrast-enhanced lesions subsequently increased and the final volume of the contrast-enhanced lesions did not reach the baseline volume at 12 months after the completion of treatment.</p></div><div id="s3c" class="sec"><h3 id="s3ctitle">KPS and Corticosteroids</h3><p class="p p-first">Among the 38 FAS patients, 16 achieved an improved KPS score (42.1%; 95% CI, 21.8%&#x02013;54%). Ten patients showed 10% improvement and 6 patients showed 20% improvement in KPS, compared with the baseline. The percentage of patients with improved KPS scores increased gradually up to 1 month after the treatment completion (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F4" rid-ob="ob-NPV064F4" co-legend-rid="lgnd_NPV064F4"><span>4</span></a>A), but decreased from 6 months after treatment completion; at 12 months posttreatment, one-half of the patients had worsened KPS scores compared with their baseline scores.

</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="NPV064F4" co-legend-rid="lgnd_NPV064F4"><a href="/pmc/articles/PMC5099992/figure/NPV064F4/" target="figure" rid-figpopup="NPV064F4" rid-ob="ob-NPV064F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139730950089248"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5099992_npv06404.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is npv06404.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5099992/bin/npv06404.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139730950089248"><a target="object" rel="noopener" href="/pmc/articles/PMC5099992/figure/NPV064F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_NPV064F4"><div><a class="figpopup" href="/pmc/articles/PMC5099992/figure/NPV064F4/" target="figure" rid-figpopup="NPV064F4" rid-ob="ob-NPV064F4">Fig.&#x000a0;4.</a></div><!--caption a7--><div class="caption"><p>Chronological changes in (A) Karnofsky performance status (KPS) and (B) corticosteroid dosage. The patients were categorized into 3 KPS groups (better, unchanged, and worse compared with the baseline).</p></div></div></div><p class="p p-last">Five patients (23.8%; 95%CI, 8.2%&#x02013;47.2%) retained better KPS scores at the last follow-up. A corticosteroid was being used by 35 patients (92.1%) at their trial enrollment. The average dexamethasone dose was 1.7 mg/day, and it was eventually reduced in 29 patients (76.3%; 95% CI, 59.8%&#x02013;88.6%). At 6 months posttreatment, the dose reached the minimum of 0.6 mg/day (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F4" rid-ob="ob-NPV064F4" co-legend-rid="lgnd_NPV064F4"><span>4</span></a>B). The final dexamethasone dose (0.8 mg/day) was still lower than the baseline dose.</p></div><div id="s3d" class="sec sec-last"><h3 id="s3dtitle">Safety</h3><p class="p p-first">Safety data until 1 month posttreatment were available for 41 patients. Adverse events occurred in 36 patients (87.8%, Table&#x000a0;<a href="/pmc/articles/PMC5099992/table/NPV064TB2/" target="table" class="fig-table-link figpopup" rid-figpopup="NPV064TB2" rid-ob="ob-NPV064TB2" co-legend-rid=""><span>2</span></a>). Ten patients (24.4%) experienced a grade 3 or greater adverse event. Hypertension was the most common adverse event, occurring in 14 patients (34.1%). Regarding adverse events that are frequently reported following bevacizumab treatment, there were 3 intracranial hemorrhages (7.3%) and 7 mucocutaneous hemorrhages (17.1%). Although 2 patients experienced a venous thromboembolic event, no patient had an arterial thromboembolic event. There were no wound-healing complications. The other grade &#x02265;3 and frequent adverse events are shown in <a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplementary material, Table S3</a>.

</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="NPV064TB2"><h3>Table&#x000a0;2.</h3><!--caption a7--><div class="caption"><p>Summary of adverse events</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="2" colspan="1">Event</th><th align="center" colspan="2" rowspan="1">Any grade<hr />
</th><th align="center" colspan="2" rowspan="1">Grade &#x02265;3<hr />
</th></tr><tr><th align="left" rowspan="1" colspan="1">No. of Patients</th><th align="left" rowspan="1" colspan="1">Percent</th><th align="left" rowspan="1" colspan="1">No. of Patients</th><th align="left" rowspan="1" colspan="1">Percent</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Any adverse event</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">87.8</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">24.4</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">34.1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4.9</td></tr><tr><td rowspan="1" colspan="1">Elevated ALT</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">31.7</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4.9</td></tr><tr><td rowspan="1" colspan="1">Convulsion</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">12.2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4.9</td></tr><tr><td rowspan="1" colspan="1">Anemia</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">29.3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2.4</td></tr><tr><td rowspan="1" colspan="1">Mucocutaneous hemorrhage</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">17.1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0</td></tr><tr><td rowspan="1" colspan="1">Proteinuria</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">12.2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0</td></tr><tr><td rowspan="1" colspan="1">Intracranial hemorrhage</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">7.3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0</td></tr><tr><td rowspan="1" colspan="1">Venous thromboembolic event</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4.9</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139730957885088"><a target="object" rel="noopener" href="/pmc/articles/PMC5099992/table/NPV064TB2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="tblfn2"><p class="p p-first-last">Abbreviation: ALT, alanine aminotransferase.</p></div></div></div><p>During the 41 patients' follow-up period (median 14.9 months), 6 patients died. The cause of death was related to the CNS in 2 patients: 1 patient's brain tumor progressed and it could not be determined whether the other patient's cerebral lesion was a tumor recurrence or BRN. The other causes of death were sepsis, malnutrition resulting in pneumonia, and pulmonary embolism. These 3 events occurred more than 4 months after the termination of bevacizumab treatments. The cause of death was unknown in 1 patient.</p><p class="p p-last">The brain tumors of 8 patients relapsed at the median time of 7.1 months (range, 2.7&#x02013;18.5 months) (<a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplementary material, Fig. S2</a>), and the metastatic brain tumor of 1 patient progressed to an original lesion in another organ.</p></div></div><div id="s4" class="tsec sec"><h2 class="head no_bottom_margin" id="s4title">Discussion</h2><p class="p p-first">Although BRN is a well-known, radiation-induced disease, and many reports have been published describing the effect of bevacizumab on BRN,<sup><a href="#NPV064C3" rid="NPV064C3" class=" bibr popnode">3</a>&#x02013;<a href="#NPV064C5" rid="NPV064C5" class=" bibr popnode">5</a>,<a href="#NPV064C16" rid="NPV064C16" class=" bibr popnode">16</a>&#x02013;<a href="#NPV064C19" rid="NPV064C19" class=" bibr popnode">19</a></sup> no formal clinical guidelines regarding BRN have been established. Our previous study's findings<sup><a href="#NPV064C15" rid="NPV064C15" class=" bibr popnode">15</a></sup> are thus quoted as the null hypothesis for the treatment response rate. We undertook a systematic review of conventional medical treatments for BRN, as described in the <a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplementary Materials</a>. Our search did not turn up any randomized studies for corticosteroids, anticoagulants, or other medications for BRN, and thus the evidence regarding conservative treatments for BRN is limited.<sup><a href="#NPV064C20" rid="NPV064C20" class=" bibr popnode">20</a>&#x02013;<a href="#NPV064C25" rid="NPV064C25" class=" bibr popnode">25</a></sup> We feel that our previous data for the treatment of 27 patients with BRN<sup><a href="#NPV064C15" rid="NPV064C15" class=" bibr popnode">15</a></sup> are sufficient and appropriate as a reference for the treatment response rate. The present study revealed a 79% response to bevacizumab that is similar to other reports of bevacizumab in BRN<sup><a href="#NPV064C3" rid="NPV064C3" class=" bibr popnode">3</a>&#x02013;<a href="#NPV064C5" rid="NPV064C5" class=" bibr popnode">5</a>,<a href="#NPV064C16" rid="NPV064C16" class=" bibr popnode">16</a>&#x02013;<a href="#NPV064C19" rid="NPV064C19" class=" bibr popnode">19</a></sup> and is also much better compared with our prior study's 15% response rate.<sup><a href="#NPV064C15" rid="NPV064C15" class=" bibr popnode">15</a></sup>
</p><p>Most of the reports showing the efficacy of bevacizumab for BRN were case studies or case reports. Only one randomized trial of symptomatic BRN patients was reported (in 2011 by Levin and colleagues).<sup><a href="#NPV064C5" rid="NPV064C5" class=" bibr popnode">5</a></sup> They established the first class I evidence that bevacizumab effectively treats BRN, and their carefully conducted study's small patient series (<em>n</em> = 14) was sufficient to provide a <em>P</em> value of .0013, which justified the small series.<sup><a href="#NPV064C5" rid="NPV064C5" class=" bibr popnode">5</a></sup> Here we enrolled the largest number of patients to date and had the longest follow-up period among the studies of BRN treated with bevacizumab.</p><p>The optimal dose and number of cycles of bevacizumab treatment for BRN are unknown, but many of the reported bevacizumab doses for BRN were the same as those used for the tumors (10 mg/kg, biweekly). As we reported earlier, we suspect that the current dose of bevacizumab (5 mg/kg) is enough to shrink perilesional edema in BRN.<sup><a href="#NPV064C2" rid="NPV064C2" class=" bibr popnode">2</a>,<a href="#NPV064C6" rid="NPV064C6" class=" bibr popnode">6</a></sup> From the viewpoint regarding the AUC, the present bevacizumab administration regimen (5 mg/kg every 2 weeks, 6 times) is equivalent to Levin's study (7.5 mg/kg, every 3 weeks, 4 times).<sup><a href="#NPV064C26" rid="NPV064C26" class=" bibr popnode">26</a></sup> The duration bevacizumab's treatment effect and the BRN relapse rate are not clear in previous reports. The main purpose of the present trial was to elucidate the remission rate and safety after 6 cycles of a 5 mg/kg dose of bevacizumab as the minimal treatment. The secondary purpose was to clarify the posttreatment course of perilesional edema after bevacizumab treatment.</p><p>Our present data revealed that bevacizumab rapidly decreased perilesional edema and achieved a high cumulative remission rate (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F2" rid-ob="ob-NPV064F2" co-legend-rid="lgnd_NPV064F2"><span>2</span></a>A and <a href="/pmc/articles/PMC5099992/figure/NPV064F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F3" rid-ob="ob-NPV064F3" co-legend-rid="lgnd_NPV064F3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and3A).</span></span><span>3</span></a>A). Bevacizumab could maintain the decrease in perilesional edema for a certain period; however, progression of the edema was observed in many cases at 9 months (median) after enrollment (Fig.&#x000a0;<a href="/pmc/articles/PMC5099992/figure/NPV064F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="NPV064F2" rid-ob="ob-NPV064F2" co-legend-rid="lgnd_NPV064F2"><span>2</span></a>B). Sixteen patients of the 38 patients in the FAS showed KPS improvement in the follow-up period, and the dose of corticosteroids decreased in most of the patients (76.3%). However, one-half of the patients did not achieve a 10% improvement in KPS score. Unfortunately, the symptomatic amelioration eventually disappeared as the perilesional edema recurred after the treatment completion. In brief, bevacizumab's therapeutic effectiveness was transient in our dosing regimen (6 cycles of 5 mg/kg). The number of doses might thus need to be increased to maintain bevacizumab's therapeutic efficacy for longer periods. Another possible option is the re-induction of bevacizumab for recurrent BRN after precedent bevacizumab treatment.</p><p>In fact, as we and others reported, BRN can recur and require an additional dose of bevacizumab; this re-challenge of bevacizumab to recurred BRN usually works well.<sup><a href="#NPV064C2" rid="NPV064C2" class=" bibr popnode">2</a>,<a href="#NPV064C5" rid="NPV064C5" class=" bibr popnode">5</a></sup> The efficacy of repeated bevacizumab against recurred BRN differed markedly from that against bevacizumab-failed tumor progression.<sup><a href="#NPV064C27" rid="NPV064C27" class=" bibr popnode">27</a>,<a href="#NPV064C28" rid="NPV064C28" class=" bibr popnode">28</a></sup>
</p><p>With regard to safety, in the present trial, the total incidence of serious adverse events (grade &#x02265;3) was 24.4%. This value is similar to the other report of bevacizumab for the treatment of BRN.<sup><a href="#NPV064C26" rid="NPV064C26" class=" bibr popnode">26</a></sup> In previous phase II and III trials of glioblastomas treated with bevacizumab,<sup><a href="#NPV064C29" rid="NPV064C29" class=" bibr popnode">29</a>&#x02013;<a href="#NPV064C31" rid="NPV064C31" class=" bibr popnode">31</a></sup> the incidences of serious adverse events were higher than those of the present trial. One of the possible reasons may be that adverse events were monitored in the present study until 1 month after treatment completion, and it is thus difficult to evaluate whether our dosing schedule as the minimum treatment reduced adverse events because there are no comparable data.</p><p>Another important problem related to the management of BRN is its diagnosis. Not only the clinical course and MRI examinations, but also objective diagnostic criteria are necessary to elucidate the effects of bevacizumab on BRN. In clinical oncology, the pathological diagnosis is definitive. Unless the case involves pure BRN, however, residual tumor cells are usually mixed with postirradiated changes in BRN. In such cases, a histological diagnosis based on a small specimen acquired by needle biopsy sometimes gives inadequate information about the lesion compared with that obtained using a whole necrotomy specimen.</p><p>In unresectable BRN, it is expected that amino-acid PET can be used to classify BRN by evaluating biological lesion activity. In this situation, the classification of BRN indicates that the perilesional edema is predominantly caused by BRN and does not refer to the absence of tumor cells. <sup>11</sup>C-MET is the most widely used amino-acid tracer in the world and in patients with CNS tumors, including gliomas and metastatic brain tumors, <sup>11</sup>C-MET PET demonstrated high sensitivity (75%&#x02013;93%) and high specificity (72.7%&#x02013;100%) for the differentiation of BRN from tumor recurrence.<sup><a href="#NPV064C7" rid="NPV064C7" class=" bibr popnode">7</a>&#x02013;<a href="#NPV064C12" rid="NPV064C12" class=" bibr popnode">12</a>,<a href="#NPV064C32" rid="NPV064C32" class=" bibr popnode">32</a></sup> We adopted <sup>18</sup>F-BPA-PET in addition to <sup>11</sup>C-MET-PET in the present study. <sup>18</sup>F-BPA-PET had shown an excellent diagnostic power for malignant gliomas activity,<sup><a href="#NPV064C33" rid="NPV064C33" class=" bibr popnode">33</a></sup> and the tracer uptake in the normal brain is less than that by <sup>11</sup>C-MET-PET, which provides high contrast in the L/N ratio between BRN and tumor progression.<sup><a href="#NPV064C13" rid="NPV064C13" class=" bibr popnode">13</a>,<a href="#NPV064C34" rid="NPV064C34" class=" bibr popnode">34</a>&#x02013;<a href="#NPV064C36" rid="NPV064C36" class=" bibr popnode">36</a></sup> This helped us predict the effectiveness of bevacizumab for BRN in our previous studies.<sup><a href="#NPV064C2" rid="NPV064C2" class=" bibr popnode">2</a>,<a href="#NPV064C6" rid="NPV064C6" class=" bibr popnode">6</a></sup> In addition, the L/N ratios of both of these types of PET exhibited a close linear relationship.<sup><a href="#NPV064C37" rid="NPV064C37" class=" bibr popnode">37</a></sup>
</p><p>While MRI is more widely used for the diagnosis of BRN than PET, our experience with PET-classified BRN led to its use in the present trial and the conclusion that the PET-based determination of BRN was an adequate predictor of bevacizumab treatment benefit. The classification of BRN by the cut-off index of tracer uptake is objective and unlikely to be influenced by inter-rater differences. Another clinical advantage of determining eligibility by amino-acid PET is its less-invasive nature. An invasive diagnostic method such as a biopsy may delay the start of bevacizumab administration due to wound healing troubles. The delayed induction of bevacizumab could make it more difficult to improve the quality of life of patients with symptomatic BRN.</p><p class="p p-last">In conclusion, the results obtained in this prospective study with a long observation period indicate that bevacizumab reduced perilesional edema at a high response rate, resulting in the improvement of performance status in patients with surgically untreatable BRN classified by amino-acid PET, although the efficacy of bevacizumab was transient in most of the patients.</p></div><div id="s5" class="tsec sec"><h2 class="head no_bottom_margin" id="s5title">Supplementary Material</h2><p class="p p-first-last">
<a href="http://nop.oxfordjournals.org/lookup/suppl/doi:10.1093/nop/npv064/-/DC1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supplementary material is available online at <em>Neuro-Oncology Practice</em> (http://neuro-oncology practice.oxfordjournals.org/)</a>.</p></div><div id="s6" class="tsec sec"><h2 class="head no_bottom_margin" id="s6title">Funding</h2><p class="p p-first-last">This work was supported by a Health and Labour Sciences Research Grant administered by Japan's Ministry of Health, Labour and Welfare (Clinical Trial on Development of New Drugs and Medical Devices, <span>H24-006</span>).</p></div><div id="sec-a.m.j" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="sec-a.m.jtitle">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="PMC_1">

<!--caption a9--><strong>Supplementary Data:</strong>

<div class="sup-box half_rhythm" id="media-a.m.j.b.b"><a href="/pmc/articles/PMC5099992/bin/supp_3_4_272__index.html" data-ga-action="click_feat_suppl">Click here to view.</a></div>

</div></div><div id="ack-a.n.a" class="tsec sec"><h2 class="head no_bottom_margin" id="ack-a.n.atitle">Acknowledgments</h2><div class="sec"><p>We thank the study participants and their families, the members of the independent safety monitoring committee (Dr. Yuta Shibamoto, Dept. of Radiology, Nagoya Municipal University, Dr. Teruki Teshima, Dept. of Radiation Oncology, Osaka Medical Center and Cardiovascular Diseases, and Dr. Takashi Daimon, Dept. of Biostatistics, Center for Clinical Support and Education, Hyogo College of Medicine), the members of the diagnostic MRI central review committee (Dr. Toshihiko Wakabayashi, Dept. of Neurosurgery, Nagoya University and Dr. Amami Kato, Dept. of Neurosurgery, Kinki University), Dr. Haruko Yamamoto (Dept. of Advanced Medical Technology Development, Research and Development Initiative Center, National Cerebral and Cardiovascular Center) for the advice regarding the draft of the protocol, and Dr. Masanori Fukushima, the director of the Translational Research Informatics Center, Foundation for Biomedical Research and Innovation (FBRI). We also thank Dr. Tohru Shiga, Dept. of Nuclear Medicine, Hokkaido University Graduate School of Medicine, for the fruitful discussion about the cut-off value in the PET study. We also thank Dr. Jonathan P.S. Knisely, Dept. of Radiation Medicine, Hofstra University, for his critical reading of the manuscript and valuable comments on it. This trial was approved as an Investigational Medical Care System and Advanced Therapy of Type B by the Ministry of Health, Labour and Welfare, Japan and was registered with the University Medical Information Network System with the assigned code UMIN000005391. The data management and statistical analyses were independently performed by the Translational Research Informatics Center, FBRI (Kobe, Japan).</p><p>
<em>Conflict of interest statement</em>. This study was conducted as a collaboration between Osaka Medical College and the Foundation for Biomedical Research &#x00026; Innovation (FBRI). As an investigator-initiated clinical study, the principal investigator (S.-I. Miyatake) was responsible for the performance of the study, with operational and technical support provided by the FBRI. The FBRI is a public-interest incorporated foundation committed to the promotion of translational and clinical research in Japan, and it receives financial support from the Japanese government and pharmaceutical/medical device companies. However, none of these companies played a role in the study design, data collection, data analysis or data interpretation of the study, or in the writing of this manuscript.</p></div></div><div id="ref-list-a.n.b" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.n.btitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="NPV064C1">1. <span class="mixed-citation">
Schoch HJ, Fischer S, Marti HH. 
<span class="ref-title">Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain</span>. <span class="ref-journal"><em>Brain</em></span>. 2002;<span class="ref-vol">125</span>
<span class="ref-iss">(Pt 11)</span>:2549&#x02013;2557. [<a href="https://pubmed.ncbi.nlm.nih.gov/12390979" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Brain&amp;title=Hypoxia-induced+vascular+endothelial+growth+factor+expression+causes+vascular+leakage+in+the+brain&amp;author=HJ+Schoch&amp;author=S+Fischer&amp;author=HH+Marti&amp;volume=125&amp;issue=(Pt+11)&amp;publication_year=2002&amp;pages=2549-2557&amp;pmid=12390979&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C2">2. <span class="mixed-citation">
Furuse M, Kawabata S, Kuroiwa T, Miyatake S. 
<span class="ref-title">Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases</span>. <span class="ref-journal"><em>J Neurooncol</em></span>. 2011;<span class="ref-vol">102</span>
<span class="ref-iss">(3)</span>:471&#x02013;475. [<a href="https://pubmed.ncbi.nlm.nih.gov/20694573" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=Repeated+treatments+with+bevacizumab+for+recurrent+radiation+necrosis+in+patients+with+malignant+brain+tumors:+a+report+of+2+cases&amp;author=M+Furuse&amp;author=S+Kawabata&amp;author=T+Kuroiwa&amp;author=S+Miyatake&amp;volume=102&amp;issue=(3)&amp;publication_year=2011&amp;pages=471-475&amp;pmid=20694573&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C3">3. <span class="mixed-citation">
Gonzalez J, Kumar AJ, Conrad CA, Levin VA. 
<span class="ref-title">Effect of bevacizumab on radiation necrosis of the brain</span>. <span class="ref-journal"><em>Int J Radiat Oncol Biol Phys</em></span>. 2007;<span class="ref-vol">67</span>
<span class="ref-iss">(2)</span>:323&#x02013;326. [<a href="https://pubmed.ncbi.nlm.nih.gov/17236958" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Effect+of+bevacizumab+on+radiation+necrosis+of+the+brain&amp;author=J+Gonzalez&amp;author=AJ+Kumar&amp;author=CA+Conrad&amp;author=VA+Levin&amp;volume=67&amp;issue=(2)&amp;publication_year=2007&amp;pages=323-326&amp;pmid=17236958&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C4">4. <span class="mixed-citation">
Torcuator R, Zuniga R, Mohan YS et al.. 
<span class="ref-title">Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis</span>. <span class="ref-journal"><em>J Neurooncol</em></span>. 2009;<span class="ref-vol">94</span>
<span class="ref-iss">(1)</span>:63&#x02013;68. [<a href="https://pubmed.ncbi.nlm.nih.gov/19189055" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=Initial+experience+with+bevacizumab+treatment+for+biopsy+confirmed+cerebral+radiation+necrosis&amp;author=R+Torcuator&amp;author=R+Zuniga&amp;author=YS+Mohan&amp;volume=94&amp;issue=(1)&amp;publication_year=2009&amp;pages=63-68&amp;pmid=19189055&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C5">5. <span class="mixed-citation">
Levin VA, Bidaut L, Hou P et al.. 
<span class="ref-title">Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system</span>. <span class="ref-journal"><em>Int J Radiat Oncol Biol Phys</em></span>. 2011;<span class="ref-vol">79</span>
<span class="ref-iss">(5)</span>:1487&#x02013;1495. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2908725/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20399573" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Randomized+double-blind+placebo-controlled+trial+of+bevacizumab+therapy+for+radiation+necrosis+of+the+central+nervous+system&amp;author=VA+Levin&amp;author=L+Bidaut&amp;author=P+Hou&amp;volume=79&amp;issue=(5)&amp;publication_year=2011&amp;pages=1487-1495&amp;pmid=20399573&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C6">6. <span class="mixed-citation">
Furuse M, Nonoguchi N, Kawabata S et al.. 
<span class="ref-title">Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET</span>. <span class="ref-journal"><em>Jpn J Clin Oncol</em></span>. 2013;<span class="ref-vol">43</span>
<span class="ref-iss">(3)</span>:337&#x02013;341. [<a href="https://pubmed.ncbi.nlm.nih.gov/23303838" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Jpn+J+Clin+Oncol&amp;title=Bevacizumab+treatment+for+symptomatic+radiation+necrosis+diagnosed+by+amino+acid+PET&amp;author=M+Furuse&amp;author=N+Nonoguchi&amp;author=S+Kawabata&amp;volume=43&amp;issue=(3)&amp;publication_year=2013&amp;pages=337-341&amp;pmid=23303838&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C7">7. <span class="mixed-citation">
Tsuyuguchi N, Sunada I, Iwai Y et al.. 
<span class="ref-title">Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?</span>
<span class="ref-journal"><em>J Neurosurg</em></span>. 2003;<span class="ref-vol">98</span>
<span class="ref-iss">(5)</span>:1056&#x02013;1064. [<a href="https://pubmed.ncbi.nlm.nih.gov/12744366" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurosurg&amp;title=Methionine+positron+emission+tomography+of+recurrent+metastatic+brain+tumor+and+radiation+necrosis+after+stereotactic+radiosurgery:+is+a+differential+diagnosis+possible?&amp;author=N+Tsuyuguchi&amp;author=I+Sunada&amp;author=Y+Iwai&amp;volume=98&amp;issue=(5)&amp;publication_year=2003&amp;pages=1056-1064&amp;pmid=12744366&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C8">8. <span class="mixed-citation">
Terakawa Y, Tsuyuguchi N, Iwai Y et al.. 
<span class="ref-title">Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy</span>. <span class="ref-journal"><em>J Nucl Med</em></span>. 2008;<span class="ref-vol">49</span>
<span class="ref-iss">(5)</span>:694&#x02013;699. [<a href="https://pubmed.ncbi.nlm.nih.gov/18413375" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=Diagnostic+accuracy+of+11C-methionine+PET+for+differentiation+of+recurrent+brain+tumors+from+radiation+necrosis+after+radiotherapy&amp;author=Y+Terakawa&amp;author=N+Tsuyuguchi&amp;author=Y+Iwai&amp;volume=49&amp;issue=(5)&amp;publication_year=2008&amp;pages=694-699&amp;pmid=18413375&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C9">9. <span class="mixed-citation">
Nakajima T, Kumabe T, Kanamori M et al.. 
<span class="ref-title">Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography</span>. <span class="ref-journal"><em>Neurol Med Chir (Tokyo)</em></span>. 2009;<span class="ref-vol">49</span>
<span class="ref-iss">(9)</span>:394&#x02013;401. [<a href="https://pubmed.ncbi.nlm.nih.gov/19779283" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurol+Med+Chir+(Tokyo)&amp;title=Differential+diagnosis+between+radiation+necrosis+and+glioma+progression+using+sequential+proton+magnetic+resonance+spectroscopy+and+methionine+positron+emission+tomography&amp;author=T+Nakajima&amp;author=T+Kumabe&amp;author=M+Kanamori&amp;volume=49&amp;issue=(9)&amp;publication_year=2009&amp;pages=394-401&amp;pmid=19779283&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C10">10. <span class="mixed-citation">
Kim YH, Oh SW, Lim YJ et al.. 
<span class="ref-title">Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI</span>. <span class="ref-journal"><em>Clin Neurol Neurosurg</em></span>. 2010;<span class="ref-vol">112</span>
<span class="ref-iss">(9)</span>:758&#x02013;765. [<a href="https://pubmed.ncbi.nlm.nih.gov/20619531" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Neurol+Neurosurg&amp;title=Differentiating+radiation+necrosis+from+tumor+recurrence+in+high-grade+gliomas:+assessing+the+efficacy+of+18F-FDG+PET,+11C-methionine+PET+and+perfusion+MRI&amp;author=YH+Kim&amp;author=SW+Oh&amp;author=YJ+Lim&amp;volume=112&amp;issue=(9)&amp;publication_year=2010&amp;pages=758-765&amp;pmid=20619531&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C11">11. <span class="mixed-citation">
Yamane T, Sakamoto S, Senda M. 
<span class="ref-title">Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm</span>. <span class="ref-journal"><em>Eur J Nucl Med Mol Imaging</em></span>. 2010;<span class="ref-vol">37</span>
<span class="ref-iss">(4)</span>:685&#x02013;690. [<a href="https://pubmed.ncbi.nlm.nih.gov/19915838" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Nucl+Med+Mol+Imaging&amp;title=Clinical+impact+of+(11)C-methionine+PET+on+expected+management+of+patients+with+brain+neoplasm&amp;author=T+Yamane&amp;author=S+Sakamoto&amp;author=M+Senda&amp;volume=37&amp;issue=(4)&amp;publication_year=2010&amp;pages=685-690&amp;pmid=19915838&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C12">12. <span class="mixed-citation">
Okamoto S, Shiga T, Hattori N et al.. 
<span class="ref-title">Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions</span>. <span class="ref-journal"><em>Ann Nucl Med</em></span>. 2011;<span class="ref-vol">25</span>
<span class="ref-iss">(3)</span>:213&#x02013;220. [<a href="https://pubmed.ncbi.nlm.nih.gov/21188660" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Nucl+Med&amp;title=Semiquantitative+analysis+of+C-11+methionine+PET+may+distinguish+brain+tumor+recurrence+from+radiation+necrosis+even+in+small+lesions&amp;author=S+Okamoto&amp;author=T+Shiga&amp;author=N+Hattori&amp;volume=25&amp;issue=(3)&amp;publication_year=2011&amp;pages=213-220&amp;pmid=21188660&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C13">13. <span class="mixed-citation">
Miyashita M, Miyatake S, Imahori Y et al.. 
<span class="ref-title">Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas</span>. <span class="ref-journal"><em>J Neurooncol</em></span>. 2008;<span class="ref-vol">89</span>
<span class="ref-iss">(2)</span>:239&#x02013;246. [<a href="https://pubmed.ncbi.nlm.nih.gov/18566749" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=Evaluation+of+fluoride-labeled+boronophenylalanine-PET+imaging+for+the+study+of+radiation+effects+in+patients+with+glioblastomas&amp;author=M+Miyashita&amp;author=S+Miyatake&amp;author=Y+Imahori&amp;volume=89&amp;issue=(2)&amp;publication_year=2008&amp;pages=239-246&amp;pmid=18566749&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C14">14. <span class="mixed-citation">
Tsuyuguchi N, Takami T, Sunada I et al.. 
<span class="ref-title">Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery&#x02013;in malignant glioma</span>. <span class="ref-journal"><em>Ann Nucl Med</em></span>. 2004;<span class="ref-vol">18</span>
<span class="ref-iss">(4)</span>:291&#x02013;296. [<a href="https://pubmed.ncbi.nlm.nih.gov/15359921" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Nucl+Med&amp;title=Methionine+positron+emission+tomography+for+differentiation+of+recurrent+brain+tumor+and+radiation+necrosis+after+stereotactic+radiosurgery&#x02013;in+malignant+glioma&amp;author=N+Tsuyuguchi&amp;author=T+Takami&amp;author=I+Sunada&amp;volume=18&amp;issue=(4)&amp;publication_year=2004&amp;pages=291-296&amp;pmid=15359921&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C15">15. <span class="mixed-citation">
Nonoguchi N, Miyatake S, Fukumoto M et al.. 
<span class="ref-title">The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles</span>. <span class="ref-journal"><em>J Neurooncol</em></span>. 2011;<span class="ref-vol">105</span>
<span class="ref-iss">(2)</span>:423&#x02013;431. [<a href="https://pubmed.ncbi.nlm.nih.gov/21688077" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=The+distribution+of+vascular+endothelial+growth+factor-producing+cells+in+clinical+radiation+necrosis+of+the+brain:+pathological+consideration+of+their+potential+roles&amp;author=N+Nonoguchi&amp;author=S+Miyatake&amp;author=M+Fukumoto&amp;volume=105&amp;issue=(2)&amp;publication_year=2011&amp;pages=423-431&amp;pmid=21688077&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C16">16. <span class="mixed-citation">
Boothe D, Young R, Yamada Y, Prager A, Chan T, Beal K. 
<span class="ref-title">Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery</span>. <span class="ref-journal"><em>Neuro Oncol</em></span>. 2013;<span class="ref-vol">15</span>
<span class="ref-iss">(9)</span>:1257&#x02013;1263. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3748921/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23814264" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro+Oncol&amp;title=Bevacizumab+as+a+treatment+for+radiation+necrosis+of+brain+metastases+post+stereotactic+radiosurgery&amp;author=D+Boothe&amp;author=R+Young&amp;author=Y+Yamada&amp;author=A+Prager&amp;author=T+Chan&amp;volume=15&amp;issue=(9)&amp;publication_year=2013&amp;pages=1257-1263&amp;pmid=23814264&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C17">17. <span class="mixed-citation">
Deibert CP, Ahluwalia MS, Sheehan JP et al.. 
<span class="ref-title">Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery</span>. <span class="ref-journal"><em>J Neurooncol</em></span>. 2013;<span class="ref-vol">115</span>
<span class="ref-iss">(2)</span>:217&#x02013;223. [<a href="https://pubmed.ncbi.nlm.nih.gov/23929592" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=Bevacizumab+for+refractory+adverse+radiation+effects+after+stereotactic+radiosurgery&amp;author=CP+Deibert&amp;author=MS+Ahluwalia&amp;author=JP+Sheehan&amp;volume=115&amp;issue=(2)&amp;publication_year=2013&amp;pages=217-223&amp;pmid=23929592&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C18">18. <span class="mixed-citation">
Wang Y, Pan L, Sheng X et al.. 
<span class="ref-title">Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients</span>. <span class="ref-journal"><em>Eur J Med Res</em></span>. 2012;<span class="ref-vol">17</span>:25. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3493338/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22913802" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Med+Res&amp;title=Reversal+of+cerebral+radiation+necrosis+with+bevacizumab+treatment+in+17+Chinese+patients&amp;author=Y+Wang&amp;author=L+Pan&amp;author=X+Sheng&amp;volume=17&amp;publication_year=2012&amp;pages=25&amp;pmid=22913802&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C19">19. <span class="mixed-citation">
Yonezawa S, Miwa K, Shinoda J et al.. 
<span class="ref-title">Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis</span>. <span class="ref-journal"><em>J Neurooncol</em></span>. 2014;<span class="ref-vol">119</span>
<span class="ref-iss">(1)</span>:101&#x02013;109. [<a href="https://pubmed.ncbi.nlm.nih.gov/24789256" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=Bevacizumab+treatment+leads+to+observable+morphological+and+metabolic+changes+in+brain+radiation+necrosis&amp;author=S+Yonezawa&amp;author=K+Miwa&amp;author=J+Shinoda&amp;volume=119&amp;issue=(1)&amp;publication_year=2014&amp;pages=101-109&amp;pmid=24789256&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C20">20. <span class="mixed-citation">
Lorenzo ND, Nolletti A, Palma L. 
<span class="ref-title">Late cerebral radionecrosis</span>. <span class="ref-journal"><em>Surg Neurol</em></span>. 1978;<span class="ref-vol">10</span>
<span class="ref-iss">(5)</span>:281&#x02013;290. [<a href="https://pubmed.ncbi.nlm.nih.gov/364708" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Surg+Neurol&amp;title=Late+cerebral+radionecrosis&amp;author=ND+Lorenzo&amp;author=A+Nolletti&amp;author=L+Palma&amp;volume=10&amp;issue=(5)&amp;publication_year=1978&amp;pages=281-290&amp;pmid=364708&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C21">21. <span class="mixed-citation">
Glass JP, Hwang TL, Leavens ME, Libshitz HI. 
<span class="ref-title">Cerebral radiation necrosis following treatment of extracranial malignancies</span>. <span class="ref-journal"><em>Cancer</em></span>. 1984;<span class="ref-vol">54</span>
<span class="ref-iss">(9)</span>:1966&#x02013;1972. [<a href="https://pubmed.ncbi.nlm.nih.gov/6478431" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Cerebral+radiation+necrosis+following+treatment+of+extracranial+malignancies&amp;author=JP+Glass&amp;author=TL+Hwang&amp;author=ME+Leavens&amp;author=HI+Libshitz&amp;volume=54&amp;issue=(9)&amp;publication_year=1984&amp;pages=1966-1972&amp;pmid=6478431&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C22">22. <span class="mixed-citation">
Woo E, Lam K, Yu YL, Lee PW, Huang CY. 
<span class="ref-title">Cerebral radionecrosis: is surgery necessary?</span>
<span class="ref-journal"><em>J Neurol Neurosurg Psychiatry</em></span>. 1987;<span class="ref-vol">50</span>
<span class="ref-iss">(11)</span>:1407&#x02013;1414. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1032549/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3694200" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol+Neurosurg+Psychiatry&amp;title=Cerebral+radionecrosis:+is+surgery+necessary?&amp;author=E+Woo&amp;author=K+Lam&amp;author=YL+Yu&amp;author=PW+Lee&amp;author=CY+Huang&amp;volume=50&amp;issue=(11)&amp;publication_year=1987&amp;pages=1407-1414&amp;pmid=3694200&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C23">23. <span class="mixed-citation">
Rizzoli HV, Pagnanelli DM. 
<span class="ref-title">Treatment of delayed radiation necrosis of the brain. A clinical observation</span>. <span class="ref-journal"><em>J Neurosurg</em></span>. 1984;<span class="ref-vol">60</span>
<span class="ref-iss">(3)</span>:589&#x02013;594. [<a href="https://pubmed.ncbi.nlm.nih.gov/6699703" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurosurg&amp;title=Treatment+of+delayed+radiation+necrosis+of+the+brain.+A+clinical+observation&amp;author=HV+Rizzoli&amp;author=DM+Pagnanelli&amp;volume=60&amp;issue=(3)&amp;publication_year=1984&amp;pages=589-594&amp;pmid=6699703&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C24">24. <span class="mixed-citation">
Glantz MJ, Burger PC, Friedman AH, Radtke RA, Massey EW, Schold SC Jr. 
<span class="ref-title">Treatment of radiation-induced nervous system injury with heparin and warfarin</span>. <span class="ref-journal"><em>Neurology</em></span>. 1994;<span class="ref-vol">44</span>
<span class="ref-iss">(11)</span>:2020&#x02013;2027. [<a href="https://pubmed.ncbi.nlm.nih.gov/7969953" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Treatment+of+radiation-induced+nervous+system+injury+with+heparin+and+warfarin&amp;author=MJ+Glantz&amp;author=PC+Burger&amp;author=AH+Friedman&amp;author=RA+Radtke&amp;author=EW+Massey&amp;volume=44&amp;issue=(11)&amp;publication_year=1994&amp;pages=2020-2027&amp;pmid=7969953&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C25">25. <span class="mixed-citation">
Happold C, Ernemann U, Roth P, Wick W, Weller M, Schmidt F. 
<span class="ref-title">Anticoagulation for radiation-induced neurotoxicity revisited</span>. <span class="ref-journal"><em>J Neurooncol</em></span>. 2008;<span class="ref-vol">90</span>
<span class="ref-iss">(3)</span>:357&#x02013;362. [<a href="https://pubmed.ncbi.nlm.nih.gov/18716713" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=Anticoagulation+for+radiation-induced+neurotoxicity+revisited&amp;author=C+Happold&amp;author=U+Ernemann&amp;author=P+Roth&amp;author=W+Wick&amp;author=M+Weller&amp;volume=90&amp;issue=(3)&amp;publication_year=2008&amp;pages=357-362&amp;pmid=18716713&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C26">26. <span class="mixed-citation">
Levin VA, Mendelssohn ND, Chan J et al.. 
<span class="ref-title">Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma</span>. <span class="ref-journal"><em>J Neurooncol</em></span>. 2015;<span class="ref-vol">122</span>
<span class="ref-iss">(1)</span>:145&#x02013;150. [<a href="https://pubmed.ncbi.nlm.nih.gov/25575937" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&amp;title=Impact+of+bevacizumab+administered+dose+on+overall+survival+of+patients+with+progressive+glioblastoma&amp;author=VA+Levin&amp;author=ND+Mendelssohn&amp;author=J+Chan&amp;volume=122&amp;issue=(1)&amp;publication_year=2015&amp;pages=145-150&amp;pmid=25575937&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C27">27. <span class="mixed-citation">
Han SJ, Rolston JD, Molinaro AM et al.. 
<span class="ref-title">Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma</span>. <span class="ref-journal"><em>Neuro Oncol</em></span>. 2014;<span class="ref-vol">16</span>
<span class="ref-iss">(9)</span>:1255&#x02013;1262. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4136897/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24670608" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro+Oncol&amp;title=Phase+II+trial+of+7+days+on/7+days+off+temozolmide+for+recurrent+high-grade+glioma&amp;author=SJ+Han&amp;author=JD+Rolston&amp;author=AM+Molinaro&amp;volume=16&amp;issue=(9)&amp;publication_year=2014&amp;pages=1255-1262&amp;pmid=24670608&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C28">28. <span class="mixed-citation">
Omuro A, Chan TA, Abrey LE et al.. 
<span class="ref-title">Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma</span>. <span class="ref-journal"><em>Neuro Oncol</em></span>. 2013;<span class="ref-vol">15</span>
<span class="ref-iss">(2)</span>:242&#x02013;250. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3548585/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23243055" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro+Oncol&amp;title=Phase+II+trial+of+continuous+low-dose+temozolomide+for+patients+with+recurrent+malignant+glioma&amp;author=A+Omuro&amp;author=TA+Chan&amp;author=LE+Abrey&amp;volume=15&amp;issue=(2)&amp;publication_year=2013&amp;pages=242-250&amp;pmid=23243055&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C29">29. <span class="mixed-citation">
Friedman HS, Prados MD, Wen PY et al.. 
<span class="ref-title">Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma</span>. <span class="ref-journal"><em>J Clin Oncol</em></span>. 2009;<span class="ref-vol">27</span>
<span class="ref-iss">(28)</span>:4733&#x02013;4740. [<a href="https://pubmed.ncbi.nlm.nih.gov/19720927" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Bevacizumab+alone+and+in+combination+with+irinotecan+in+recurrent+glioblastoma&amp;author=HS+Friedman&amp;author=MD+Prados&amp;author=PY+Wen&amp;volume=27&amp;issue=(28)&amp;publication_year=2009&amp;pages=4733-4740&amp;pmid=19720927&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C30">30. <span class="mixed-citation">
Lai A, Filka E, McGibbon B et al.. 
<span class="ref-title">Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability</span>. <span class="ref-journal"><em>Int J Radiat Oncol Biol Phys</em></span>. 2008;<span class="ref-vol">71</span>
<span class="ref-iss">(5)</span>:1372&#x02013;1380. [<a href="https://pubmed.ncbi.nlm.nih.gov/18355978" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Radiat+Oncol+Biol+Phys&amp;title=Phase+II+pilot+study+of+bevacizumab+in+combination+with+temozolomide+and+regional+radiation+therapy+for+up-front+treatment+of+patients+with+newly+diagnosed+glioblastoma+multiforme:+interim+analysis+of+safety+and+tolerability&amp;author=A+Lai&amp;author=E+Filka&amp;author=B+McGibbon&amp;volume=71&amp;issue=(5)&amp;publication_year=2008&amp;pages=1372-1380&amp;pmid=18355978&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C31">31. <span class="mixed-citation">
Chinot OL, Wick W, Mason W et al.. 
<span class="ref-title">Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma</span>. <span class="ref-journal"><em>N Engl J Med</em></span>. 2014;<span class="ref-vol">370</span>
<span class="ref-iss">(8)</span>:709&#x02013;722. [<a href="https://pubmed.ncbi.nlm.nih.gov/24552318" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Bevacizumab+plus+radiotherapy-temozolomide+for+newly+diagnosed+glioblastoma&amp;author=OL+Chinot&amp;author=W+Wick&amp;author=W+Mason&amp;volume=370&amp;issue=(8)&amp;publication_year=2014&amp;pages=709-722&amp;pmid=24552318&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C32">32. <span class="mixed-citation">
Van Laere K, Ceyssens S, Van Calenbergh F et al.. 
<span class="ref-title">Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value</span>. <span class="ref-journal"><em>Eur J Nucl Med Mol Imaging</em></span>. 2005;<span class="ref-vol">32</span>
<span class="ref-iss">(1)</span>:39&#x02013;51. [<a href="https://pubmed.ncbi.nlm.nih.gov/15309329" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Nucl+Med+Mol+Imaging&amp;title=Direct+comparison+of+18F-FDG+and+11C-methionine+PET+in+suspected+recurrence+of+glioma:+sensitivity,+inter-observer+variability+and+prognostic+value&amp;author=K+Van+Laere&amp;author=S+Ceyssens&amp;author=F+Van+Calenbergh&amp;volume=32&amp;issue=(1)&amp;publication_year=2005&amp;pages=39-51&amp;pmid=15309329&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C33">33. <span class="mixed-citation">
Takahashi Y, Imahori Y, Mineura K. 
<span class="ref-title">Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas</span>. <span class="ref-journal"><em>Clin Cancer Res</em></span>. 2003;<span class="ref-vol">9</span>
<span class="ref-iss">(16 Pt 1)</span>:5888&#x02013;5895. [<a href="https://pubmed.ncbi.nlm.nih.gov/14676111" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Prognostic+and+therapeutic+indicator+of+fluoroboronophenylalanine+positron+emission+tomography+in+patients+with+gliomas&amp;author=Y+Takahashi&amp;author=Y+Imahori&amp;author=K+Mineura&amp;volume=9&amp;issue=(16+Pt+1)&amp;publication_year=2003&amp;pages=5888-5895&amp;pmid=14676111&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C34">34. <span class="mixed-citation">
Miyatake S, Kawabata S, Nonoguchi N et al.. 
<span class="ref-title">Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas</span>. <span class="ref-journal"><em>Neuro Oncol</em></span>. 2009;<span class="ref-vol">11</span>
<span class="ref-iss">(4)</span>:430&#x02013;436. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2743223/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19289492" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro+Oncol&amp;title=Pseudoprogression+in+boron+neutron+capture+therapy+for+malignant+gliomas+and+meningiomas&amp;author=S+Miyatake&amp;author=S+Kawabata&amp;author=N+Nonoguchi&amp;volume=11&amp;issue=(4)&amp;publication_year=2009&amp;pages=430-436&amp;pmid=19289492&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C35">35. <span class="mixed-citation">
Miyatake S, Furuse M, Kawabata S et al.. 
<span class="ref-title">Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases</span>. <span class="ref-journal"><em>Neuro Oncol</em></span>. 2013;<span class="ref-vol">15</span>
<span class="ref-iss">(6)</span>:650&#x02013;655. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3661101/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23460324" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro+Oncol&amp;title=Bevacizumab+treatment+of+symptomatic+pseudoprogression+after+boron+neutron+capture+therapy+for+recurrent+malignant+gliomas.+Report+of+2+cases&amp;author=S+Miyatake&amp;author=M+Furuse&amp;author=S+Kawabata&amp;volume=15&amp;issue=(6)&amp;publication_year=2013&amp;pages=650-655&amp;pmid=23460324&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C36">36. <span class="mixed-citation">
Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M. 
<span class="ref-title">Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases</span>. <span class="ref-journal"><em>Radiat Oncol</em></span>. 2014;<span class="ref-vol">9</span>:6. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3923505/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24387301" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Radiat+Oncol&amp;title=Boron+neutron+capture+therapy+with+bevacizumab+may+prolong+the+survival+of+recurrent+malignant+glioma+patients:+four+cases&amp;author=S+Miyatake&amp;author=S+Kawabata&amp;author=R+Hiramatsu&amp;author=M+Furuse&amp;author=T+Kuroiwa&amp;volume=9&amp;publication_year=2014&amp;pages=6&amp;pmid=24387301&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="NPV064C37">37. <span class="mixed-citation">
Nariai T, Ishiwata K, Kimura Y et al.. 
<span class="ref-title">PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma</span>. <span class="ref-journal"><em>Appl Radiat Isot</em></span>. 2009;<span class="ref-vol">67</span>
<span class="ref-iss">(7&#x02013;8 Suppl)</span>:S348&#x02013;S350. [<a href="https://pubmed.ncbi.nlm.nih.gov/19375930" ref="reftype=pubmed&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Appl+Radiat+Isot&amp;title=PET+pharmacokinetic+analysis+to+estimate+boron+concentration+in+tumor+and+brain+as+a+guide+to+plan+BNCT+for+malignant+cerebral+glioma&amp;author=T+Nariai&amp;author=K+Ishiwata&amp;author=Y+Kimura&amp;volume=67&amp;issue=(7&#x02013;8+Suppl)&amp;publication_year=2009&amp;pages=S348-S350&amp;pmid=19375930&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5099992&amp;issue-id=278756&amp;journal-id=2697&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Neuro-Oncology Practice</span> are provided here courtesy of <strong>Oxford University Press</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC5099992/pdf/npv064.pdf" class="int-view">PDF (4.2M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/5099992/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/5099992/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="5099992" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5099992%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="pRaxOh9jbBPvCzhbe84cOwZqgkyeWa0PcKd6xIGm6E2frWA0kezIMGblPYYYMnpE">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5099992%2F&amp;text=A%20prospective%2C%20multicentre%2C%20single-arm%20clinical%20trial%20of%20bevacizumab%20for%20patients%20with%20surgically%20untreatable%2C%20symptomatic%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5099992%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099992/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC5099992/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/27833757/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC5099992/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/27833757/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC5099992/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/5099992/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC5099992/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
